Loading...
•
Sep 30
Tonix Q3 2025 Earnings Report
Tonix posted a wider net loss in Q3 2025 driven by a significant increase in SG&A expenses ahead of the Tonmya launch.
Key Takeaways
Tonix Pharmaceuticals reported a net loss of $32 million in Q3 2025 as the company ramped up commercial operations for the upcoming Tonmya launch. Revenues increased modestly, but elevated R&D and SG&A expenditures weighed heavily on the bottom line.
Net product revenue reached $3.3 million, a slight increase from the prior year.
Net loss widened to $32 million in Q3 2025, compared to $14.2 million in Q3 2024.
General and administrative expenses surged to $25.7 million due to Tonmya pre-launch investments.
Cash and cash equivalents stood at $190.1 million, expected to fund operations into Q1 2027.
Tonix
Tonix
Tonix Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.com Forward Guidance
Tonix plans to commercialize Tonmya for fibromyalgia in Q4 2025 while continuing to advance a diverse pipeline with multiple mid-stage assets.
Positive Outlook
- Tonmya set to launch in November 2025 following FDA approval.
- Commercial infrastructure, market access, and distribution fully in place.
- Tosymra gaining formulary access for 16 million covered lives starting Jan 2026.
- TNX-1500 moving into Phase 2 study for kidney transplant prevention in H1 2026.
- Cash runway extends into Q1 2027.
Challenges Ahead
- High SG&A spend ahead of Tonmya commercialization inflating quarterly losses.
- R&D costs remain elevated due to manufacturing investments.
- Net loss widened significantly year-over-year.
- Product revenue growth remains modest ahead of Tonmya launch.
- Dependency on capital markets for funding in the medium term.